Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis
2024-518785-28-00Phase 4Authorised
- Sponsor
- Istituto Giannina Gaslini
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of elexacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Istituto Giannina Gaslini. Primary endpoint: Steady-state plasma concentrations of elexacaftor, tezacaftor, and ivacaftor. Planned start Sep 2026; status: authorised.
02
Drugs
elexacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2024-518785-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518785-28-00.